Hepion shareholders approve reverse stock split (1:10-1:50) at annual meeting

Hepion Pharmaceuticals, Inc.

All four director nominees elected (Brancaccio, Block, Lbiati, Purcell) with majority 'For' votes.
Ratification of Grassi & Co. as auditor for FY2024 approved: 2,974,800 For, 603,560 Against.
Advisory say-on-pay approved: 1,419,035 For, 853,863 Against, 244,418 Abstentions.
Issuance of shares upon Series A and B Warrants approved: 1,720,659 For, 793,847 Against.
Reverse stock split amendment approved (2,685,475 For); board to set ratio (1:10-1:50) and timing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.